Zacks Investment Research·Sep 9, 2026
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.
Amarin's fundamental outlook is challenged by a 42% year-over-year revenue decline in 2026Q2 to $42.2M, with gross margin compressing to 35.5% from 69.2% a year earlier. The company's cost structure remains unsustainable, as SG&A of $22.2M exceeds gross profit...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | -$0.02-100.0% vs -$0.01 | $42M-5.3% vs $45M |
Q2 2026 Apr 29, 2026 | -$0.09-1000.0% vs $0.01 | $45M+3.1% vs $44M |
Q1 2026 Feb 25, 2026 | $0.01-85.7% vs $0.07 | $49M-2.8% vs $51M |
Q4 2025 Oct 29, 2025 | $0.01-87.5% vs $0.08 | $50M+15.2% vs $43M |
Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA)
DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc analysis from the landmark REDUCE-IT® cardiovascular outcomes trial, presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany.
DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026, August 28t h - 31st, in Munich, Germany.
Benchmark AMRN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Amarin Corporation plc (AMRN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.75 | $5.73B | -7.64 | -6.55% | -18.16% | -8.21% | — | |
| $22.92 | $11.45B | -48.77 | 6.22% | -3.96% | -3.02% | — | |
| $26.41 | $4.52B | 11.53 | 11.87% | 33.42% | 32.39% | — | |
| $43.75 | $2.54B | -64.34 | 8.63% | -13.23% | -10.42% | — | |
| $41.53 | $2.4B | 15.32 | 21.51% | 18.88% | 20.06% | — | |
| $14.31 | $1.98B | -1.39 | -2.75% | -41.85% | -55.97% | — |
Amarin Corporation plc (AMRN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Amarin Corporation plc (AMRN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
May 15, 2026·SEC
Apr 29, 2026·SEC
Get notified when AMRN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Amarin Corporation plc (AMRN) stock FAQ — growth, dividends, profitability & financials explained
Amarin Corporation plc (AMRN) reported $184.4M in revenue for fiscal year 2025. This represents a 757% increase from $21.5M in 1996.
Amarin Corporation plc (AMRN) saw revenue decline by 6.5% over the past year.
Amarin Corporation plc (AMRN) reported a net loss of $27.1M for fiscal year 2025.
Amarin Corporation plc (AMRN) has a return on equity (ROE) of -8.2%. Negative ROE indicates the company is unprofitable.
Amarin Corporation plc (AMRN) generated $49.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
